16th Dec 2015 10:58
LONDON (Alliance News) - Ergomed PLC said Wednesday that its pipeline of co-development partnerships are on track, and it will provide updates on two late stage clinical data readouts in 2016.
The company has four active partnerships with companies that have studies in late stage development. With New York-listed CEL-SCI Corp, it is running a phase III study in head and neck cancer with Multikine. With Aeterna Zentaris Inc, its study with Zoptrex for endometrial cancer is "proceeding well", it said, with final results expected in 2016.
It is collaborating with Spanish pharmaceutical company Grupo Ferrer Internacional SA to develop its insomnia treatment Lorediplon, with a phase IIa study scheduled to complete by late 2016. Meanwhile, it is working with Dilaflorette AB on a phase IIa study for sevuparin as a potential sickle-cell disease treatment. It started recruiting for a phase II study in October.
"Our growing pipeline of co-development partnerships is on track and we are looking forward to providing updates on two late stage clinical data readouts in 2016. As we continue to see opportunities in this sector and as the portfolio expands we will be in a strong position to place more emphasis on this division of our business," said Chief Executive Officer Miroslav Reljanovic in a statement.
Shares in Ergomed were up 2.1% at 171.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L